Ginger for Migraine and Pain
The most-discussed piece of evidence in the ginger-migraine literature is the Maghbooli 2014 Iranian head-to-head trial published in Phytotherapy Research: in 100 patients with migraine without aura, ginger powder and sumatriptan gave statistically comparable relief of migraine attacks, and ginger had fewer side effects. Sumatriptan is the prototypical "triptan" serotonin-receptor agonist and remains one of the most effective acute migraine drugs; a botanical comparable to it in a head-to-head comparison is rare. The picture is mixed, though: the Rondanelli 2020 narrative review in the same journal counted a single migraine trial among a decade of ginger pain trials, a 2020 Brazilian trial found ginger no better than placebo for preventing attacks, and a 2026 meta-analysis rated all the migraine evidence low to very low certainty. The proposed mechanism is convergent: ginger's COX/LOX inhibition addresses the prostaglandin component of migraine pain, 5-HT3 antagonism addresses the migraine-associated nausea, and a sublingual / under-the-tongue route (used in the Cady 2011 feverfew-ginger product) is meant to bypass the migraine-impaired gastric absorption that often defeats oral triptans during a bad attack. Ginger's pain-relieving role extends beyond migraine to dysmenorrhea, exercise-induced muscle pain, and chronic musculoskeletal pain — covered in cross-link to the Anti-Inflammatory page.
Table of Contents
- The Migraine Pharmacology Problem
- Maghbooli 2014 — Ginger vs Sumatriptan Head-to-Head
- Martins 2019 — Ginger Added to Ketoprofen in the Emergency Room
- Rondanelli 2020 — Narrative Review of Ginger for Pain
- Why the Sublingual Route Matters in Migraine
- Multi-Target Mechanism — COX/LOX, 5-HT3, CGRP, TRPV1
- Combination with Feverfew — Cady 2011
- Dysmenorrhea Pain
- Muscle Pain and Eccentric-Exercise DOMS
- Chronic Pain and the Opioid-Sparing Angle
- What the Migraine Trials Gave
- Ginger for Migraine Prevention: A Negative Trial
- What the 2026 Meta-Analysis Found
- Cautions and Drug Interactions
- Key Research Papers
- Connections
- Featured Videos
The Migraine Pharmacology Problem
Migraine affects roughly 12% of the adult population (about 18% of women, 6% of men) and is one of the leading causes of disability globally. The pharmacologic toolkit for acute migraine treatment has expanded substantially in the last 30 years but still leaves major unmet needs:
- Nonsteroidal anti-inflammatory drugs (NSAIDs) — aspirin, ibuprofen, naproxen, diclofenac. Cheap, available, modest efficacy for mild-to-moderate migraine. Limited by gastrointestinal (GI) toxicity, anticoagulant interactions, and the fact that gastric absorption is impaired during migraine attacks (gastroparesis is a common migraine feature).
- Triptans — sumatriptan, rizatriptan, eletriptan, zolmitriptan, etc. 5-HT1B/1D agonists that cause cranial vasoconstriction and reduce inflammatory neuropeptide release. Effective in roughly 60% of patients. Limited by cardiovascular contraindications (cannot use in patients with coronary artery disease (CAD), uncontrolled hypertension, prior stroke), tachyphylaxis (medication-overuse headache from frequent use), cost, and the same gastric absorption problem during attacks.
- Ergot alkaloids — dihydroergotamine (DHE). Older drug class with similar mechanism but more vasoconstrictive side effects. Now used mainly intravenous (IV) for status migrainosus or nasal spray.
- CGRP antagonists (gepants) — ubrogepant, rimegepant. New oral acute-treatment class targeting the calcitonin-gene-related peptide pathway central to migraine. Effective and well-tolerated but very expensive ($800–1000/month).
- Antiemetics — metoclopramide, prochlorperazine. Used adjunctively for the nausea component and to improve absorption of co-administered analgesics.
- Preventives — beta-blockers, topiramate, valproate, amitriptyline, anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab). Used for frequent migraine to reduce attack frequency rather than treat individual attacks.
The therapeutic gap that ginger occupies: patients who cannot use triptans (cardiovascular contraindications, pregnancy, breastfeeding, recurrent medication-overuse headache from triptan use, intolerance, or cost), patients who experience prominent nausea/vomiting during attacks (where gastric absorption is impaired and they cannot keep oral medications down), and patients who want a low-cost first-line approach before escalating to prescription medications.
Maghbooli 2014 — Ginger vs Sumatriptan Head-to-Head
The Maghbooli, Golipour, Moghimi Esfandabadi, and Yousefi randomized double-blind trial published in Phytotherapy Research in 2014 is the pivotal study. What the published abstract describes:
- 100 patients with acute migraine without aura, from Zanjan University of Medical Sciences in Iran
- Randomly allocated to ginger powder or sumatriptan; a 2024 review of migraine supplements (Hajhashemy and colleagues) gives the doses as 250 mg ginger powder and 50 mg sumatriptan. The abstract does not state the route.
- Patients recorded the time of headache onset, its severity, the time from headache start to taking the drug, and their own estimate of response, for five subsequent migraine attacks
- Satisfaction with treatment and willingness to continue were assessed one month after the intervention
Key results, as the abstract reports them:
- Two hours after either drug, mean headache severity had fallen significantly
- The efficacy of ginger powder and sumatriptan was similar — “statistically comparable”
- Clinical adverse effects were fewer with ginger powder than with sumatriptan
- Patients' satisfaction and willingness to continue did not differ between the groups
The fact that ginger matched sumatriptan in this single trial does not mean ginger is "as good as" sumatriptan for every migraine patient — the trial enrolled migraine without aura, used ginger powder, and the comparator sumatriptan (at the 50 mg dose the later review reports) is a moderate oral dose rather than 100 mg, the maximum oral dose, or 6 mg subcutaneous, the most potent route. Independent replication is still needed.
What the trial reports: in the population studied, ginger powder was statistically comparable to sumatriptan for acute migraine attacks, with fewer side effects. This is an unusual finding for a botanical medicine in head-to-head comparison with a modern pharmaceutical, and it has driven substantial subsequent research interest.
Martins 2019 — Ginger Added to Ketoprofen in the Emergency Room
A double-blind, placebo-controlled randomized trial in the emergency room of a general hospital (Martins and colleagues, Cephalalgia 2019) enrolled 60 adults with episodic migraine (one to six attacks a month) who came in during an attack. All received 100 mg of intravenous ketoprofen, a nonsteroidal anti-inflammatory drug; in addition they took 400 mg ginger extract (5% active ingredient) or placebo (cellulose). The ginger group had a significantly better clinical response at 1 hour (p = 0.04), 1.5 hours (p = 0.01) and 2 hours (p = 0.04), with less pain and better functional status at all times assessed. The authors concluded that adding ginger to nonsteroidal anti-inflammatory drugs may contribute to the treatment of a migraine attack.
Rondanelli 2020 — Narrative Review of Ginger for Pain
Rondanelli, Fossari, Vecchio, Gasparri, Peroni, Spadaccini, Riva, Petrangolini, Iannello, Nichetti, Infantino, and Perna published a narrative review in Phytotherapy Research in 2020 of the randomized controlled trials of ginger for pain from the preceding ten years (2008–2018). The scope and findings:
- Conditions covered: five — primary dysmenorrhea, delayed-onset muscle soreness (DOMS), knee osteoarthritis, chronic low back pain, and migraine
- Primary dysmenorrhea: six eligible trials suggest a promising effect of oral ginger
- Delayed-onset muscle soreness: four trials suggested reduced inflammation after oral and topical ginger
- Knee osteoarthritis: nine trials, most finding oral and topical ginger effective against pain, while others found no significant difference
- Chronic low back pain: one trial, of Swedish massage with aromatic ginger oil, which reduced pain
- Migraine: one trial
- Conclusion: the authors describe ginger for pain as “safe and promising,” while more studies are needed to reach a consensus on the dose for long-term use
For migraine specifically, the one trial the Rondanelli review included is the Cady 2011 trial of a sublingual feverfew-ginger product, which the review calls “the first effort” to elucidate ginger's use in migraine. The older Mustafa & Srivastava 1990 paper in Journal of Ethnopharmacology proposed ginger for migraine based on its reported use in Ayurvedic and Tibb medicine.
Where this places ginger: interest in it comes mostly from people looking for a botanical approach to migraine, people with triptan contraindications or poor triptan tolerability, and people facing cost or access barriers to prescription acute-migraine treatment. The evidence does not show it as a substitute for triptans in people who tolerate and respond to them.
Why the Sublingual Route Matters in Migraine
The sublingual / buccal route of administration belongs to the Cady 2011 trial, which tested a feverfew-ginger product placed under the tongue; the Maghbooli abstract describes only “ginger powder” and gives no route. A sublingual preparation is meant to be absorbed through the lining of the mouth into the systemic circulation, bypassing the stomach.
This matters because migraine is associated with prominent gastroparesis during attacks. Multiple studies have documented dramatically slowed gastric emptying in active migraine — T½ can be 2–5 times normal during a moderate-to-severe attack. The mechanism is autonomic: the same trigeminovascular activation that produces the headache also triggers vagal-parasympathetic disturbance and gastric paresis. The practical consequence: oral medications taken during a migraine attack are absorbed poorly and unpredictably. A sumatriptan tablet taken at attack onset may sit in the stomach for hours before being absorbed, by which time the attack may have progressed past the optimal treatment window.
This is why migraine specialists frequently prescribe:
- Sumatriptan nasal spray (5 or 20 mg) or subcutaneous injection (4 or 6 mg) rather than oral tablets
- Zolmitriptan nasal spray
- Dihydroergotamine nasal spray or injection
- Metoclopramide co-administration to accelerate gastric emptying of co-administered oral analgesics
- Rectal indomethacin or diclofenac suppositories for severe attacks
Sublingual ginger fits this same logic: it bypasses the unreliable migraine-impaired gastric absorption, delivering the active gingerols directly to systemic circulation through buccal mucosa. The Cady 2011 trial (discussed below) used a sublingual feverfew-ginger product.
Some people who use ginger for acute migraine describe opening a ginger powder capsule and letting the powder dissolve under the tongue over 2–3 minutes instead of swallowing it, or holding a ginger lozenge or strong ginger candy under the tongue. The taste is intensely pungent (gingerols activate the TRPV1 receptor, the same target as capsaicin). How much this changes absorption has not been measured in the trials cited here.
Multi-Target Mechanism — COX/LOX, 5-HT3, CGRP, TRPV1
Ginger's anti-migraine mechanism is convergent across multiple pathways relevant to migraine pathophysiology:
- Cyclooxygenase-1 (COX-1) / cyclooxygenase-2 (COX-2) inhibition — reduces prostaglandin synthesis during the trigeminovascular activation that drives migraine pain. This is the same mechanism by which nonsteroidal anti-inflammatory drugs (aspirin, ibuprofen, naproxen) work for acute migraine. Discussed at length in the Anti-Inflammatory page.
- 5-LOX inhibition — reduces leukotriene synthesis. Leukotrienes contribute to inflammatory vascular leak and neutrophil recruitment, both relevant to migraine's vascular/inflammatory cascade. Nonsteroidal anti-inflammatory drugs do not provide this; ginger's dual COX+LOX inhibition is mechanistically broader.
- 5-HT3 antagonism — reduces the nausea and vomiting component of migraine that is mechanistically distinct from the headache.
- CGRP modulation — preliminary evidence suggests ginger compounds may reduce calcitonin-gene-related peptide release from trigeminal nerves. CGRP is the central mediator of modern migraine pathophysiology — the entire new class of anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) and small-molecule CGRP receptor antagonists (gepants: ubrogepant, rimegepant) is built around blocking this peptide. If ginger reduces CGRP release as preclinical data suggest, this would be a mechanistic explanation for the head-to-head result with sumatriptan.
- TRPV1 modulation — 6-shogaol activates TRPV1 (the capsaicin receptor) and may produce a paradoxical analgesic effect through desensitization, similar to the way repeated capsaicin application reduces neuropathic pain over time. The acute pungent "burn" sensation when sublingual ginger is taken is TRPV1 activation; whether this contributes to the migraine analgesic effect or is merely a side effect is uncertain.
- Substance P / NK1 receptor — ginger compounds have modest activity at the NK1 receptor (the same target as aprepitant), which may contribute to both the antiemetic and the anti-inflammatory components of migraine response.
The multi-target profile is a recurring theme in botanical pharmacology and one reason single-target synthetic drugs sometimes underperform whole-plant or whole-extract therapies in clinical trials of complex multi-mechanism diseases like migraine.
Combination with Feverfew — Cady 2011
Feverfew (Tanacetum parthenium) is the other major botanical with anti-migraine evidence. Its principal active compound, parthenolide, inhibits serotonin release from platelets, inhibits NF-κB, and has been used traditionally for migraine prophylaxis since at least the 17th century in European herbal medicine. The combination of feverfew and ginger has plausibility because the two herbs target different pathways: ginger acts acutely on prostaglandins/leukotrienes/5-HT3/nausea, while feverfew acts on platelet serotonin and inflammatory mediators.
The Cady 2011 trial published in Headache tested a commercial sublingual product combining feverfew and ginger, designed for absorption through the lining of the mouth. Protocol:
- Multi-center pilot randomized double-blind placebo-controlled trial with 60 patients, randomized 3:1 (45 to the feverfew-ginger product, 15 to placebo), who treated 221 attacks over one month
- Sublingual feverfew-ginger combination vs matching sublingual placebo, taken at the earliest recognition of migraine, in people who could identify a mild-headache phase in at least 75% of attacks
- Outcomes: pain freedom, pain reduction, and recurrence at standard time points
Results: at 2 hours, 32% of people on the active combination were pain-free vs 16% with placebo (P = .02), and 63% had pain relief (pain-free or mild headache) vs 39% (P = .002); no serious adverse events. The side effects reported most often were mouth numbness and nausea. Because the product combined feverfew and ginger, the trial cannot show how much of the effect came from ginger itself. The trial was preliminary (small sample, pilot design) but supported the broader rationale for sublingual botanical combinations in acute migraine.
Standardized feverfew preparations (containing >= 0.2% parthenolide) at 50–125 mg/day are used both for prophylaxis (daily) and for acute use (at attack onset) in some protocols. Sublingual feverfew-ginger products are sold; their quality varies, and parthenolide content is the measure used to standardize feverfew.
For more on feverfew specifically, see our Feverfew page (under Herbs).
Dysmenorrhea Pain
Primary dysmenorrhea is driven primarily by elevated PGF2-alpha and PGE2 produced by the menstruating endometrium. Ginger's COX/LOX inhibition is the same mechanism by which nonsteroidal anti-inflammatory drugs work for menstrual pain, and multiple randomized trials confirm ginger's non-inferiority to nonsteroidal anti-inflammatory drugs for this indication. The Ozgoli 2009 trial (covered in the Anti-Inflammatory page) is the foundational comparison.
What the dysmenorrhea trials gave: in the Ozgoli 2009 trial, 250 mg capsules of ginger rhizome powder four times a day for three days from the start of the menstrual period (150 students; ginger was as effective as mefenamic acid and ibuprofen); in the Rahnama 2012 trial, 500 mg ginger root powder three times a day, either from two days before the period through its first three days, or for the first three days only. For women whose migraine attacks cluster around menstruation ("menstrual migraine"), ginger has been proposed for both problems at once, either around menstruation or at attack onset; this use has not been tested in the trials cited here.
Muscle Pain and Eccentric-Exercise DOMS
The Black 2010 trial in Journal of Pain (covered in detail in the Anti-Inflammatory page) demonstrated significant reduction in delayed-onset muscle soreness with 2 g/day of ginger taken for 11 days surrounding an eccentric-exercise protocol. The mechanism is the same anti-inflammatory action applied to mechanically damaged muscle fibers.
For chronic musculoskeletal pain — chronic low back pain, fibromyalgia, neck pain, tendinopathy — ginger's evidence is less robust than for the specific indications above, and its use rests on open-label reports and traditional use. Doses described in practice are 500–1000 mg ginger powder twice a day with meals for at least 4 weeks; no trial cited here tested that regimen for these conditions.
For neuropathic pain (diabetic neuropathy, post-herpetic neuralgia), ginger's TRPV1 effects suggest theoretical benefit but clinical evidence is limited. The well-studied TRPV1 desensitization approach uses the capsaicin 8% skin patch rather than oral ginger. Topical ginger preparations may produce some local TRPV1 effect for localized neuropathic pain.
Chronic Pain and the Opioid-Sparing Angle
The opioid crisis has driven renewed interest in non-opioid analgesic strategies, including botanical and supplement options. Ginger occupies a small but real role in this landscape — it is not an opioid replacement for severe acute pain or cancer-related pain, but it is a credible adjunctive option for chronic non-malignant musculoskeletal pain that may allow reduced opioid dosing in patients who have been on long-term opioid therapy.
The opioid-sparing approach in chronic pain, as integrative pain-medicine protocols describe it:
- Non-opioid medicines: nonsteroidal anti-inflammatory drugs (within gastrointestinal/renal tolerance), acetaminophen, antidepressants (duloxetine for chronic musculoskeletal, amitriptyline for sleep-disrupted pain), gabapentin or pregabalin for neuropathic component
- Supplements used in these protocols: ginger 500 mg twice a day, turmeric/curcumin 500 mg twice a day, omega-3 2 g/day, vitamin D where deficient, magnesium
- Non-drug management: physical therapy, cognitive behavioral therapy for pain, sleep optimization, weight management if applicable
- A gradual opioid taper (10% per month is the typical conservative pace) with functional status monitored
- Treatment of the underlying disease where possible (joint replacement, surgical correction)
Ginger's role in this protocol is as one of several adjunctive agents that may, in aggregate, allow meaningful opioid dose reduction without loss of functional pain control. It is not by itself a substitute for opioids in patients with severe chronic pain, but it contributes alongside the other modalities.
For more on the broader chronic-pain management approach, see our Chronic Pain page.
What the Migraine Trials Gave
The doses and timing used in the migraine trials described on this page:
- Maghbooli 2014 — ginger powder against sumatriptan for acute attacks (250 mg ginger and 50 mg sumatriptan, as a later review reports the doses), recorded over five attacks.
- Cady 2011 — a sublingual feverfew-ginger product placed under the tongue at the earliest recognition of a migraine, in people who usually have a mild-headache phase first; as the Rondanelli review describes the protocol, a second dose was allowed if pain persisted at 1 hour.
- Martins 2019 — 400 mg ginger extract (5% active ingredient) or placebo, in addition to 100 mg intravenous ketoprofen, in an emergency room.
- Martins 2020 — 200 mg dry ginger extract (5% active ingredient) three times a day for three months, for prevention; no better than placebo.
Pain in these trials was assessed at 2 hours. Comfort measures that people with migraine commonly describe alongside any treatment — lying down in a dark, quiet room, a cool compress on the forehead or back of the neck, small sips of water — are part of the usual migraine routine rather than findings of these trials. Ginger lozenges, fresh ginger root chewed slowly, or strong ginger tea sipped in small amounts are other forms people use when nausea is strong; none was tested in these trials. An attack not relieved by 2 hours is the point at which rescue medication (typically a triptan, an ergot, or a higher-dose nonsteroidal anti-inflammatory drug) is commonly used.
A daily-supplementation regimen (1 g/day), discussed in the cross-cutting Research Papers of the Benefits hub, has been proposed for prevention through the chronic anti-inflammatory mechanism; the one placebo-controlled prevention trial of ginger alone (Martins 2020, below) found it no better than placebo.
Ginger for Migraine Prevention: A Negative Trial
A double-blind, placebo-controlled trial at the headache clinic of the Universidade Federal de Minas Gerais in Brazil (Martins and colleagues, Cephalalgia 2020) enrolled 107 adults aged 18–60 with episodic migraine who were not taking a preventive medicine. After one month of observation they were randomized to capsules of 200 mg dry ginger extract (5% active ingredient) or placebo (cellulose) three times a day for three months. The share of people whose number of attacks fell by half did not differ between the groups. Days with severe pain, use of acute migraine painkillers and attack duration fell in both groups, with no significant difference between ginger and placebo. The authors concluded that ginger “provides no greater benefit in the prophylactic treatment of migraine when compared to placebo.”
What the 2026 Meta-Analysis Found
A 2026 systematic review and meta-analysis (Atkins, Manger and Albarqouni, BMJ Evidence-Based Medicine) pooled eight randomized controlled trials with 594 patients. For acute treatment, ginger added to ketoprofen gave a mean headache severity 1.27 points lower at 2 hours than placebo added to ketoprofen (one trial, 60 people), which the authors graded as low-certainty evidence that may make little to no difference. Whether ginger with feverfew beat placebo, or ginger alone matched sumatriptan, was rated very uncertain. For prevention, ginger added to an active preventive drug lowered headache pain severity at 3 months compared with the same drug alone (two trials, 183 people; low certainty). Whether ginger combined with other herbs matched valproic acid or amitriptyline was very uncertain. The certainty of all the evidence ranged from low to very low, and the authors concluded that it is currently too uncertain whether ginger is effective for either acute treatment or prevention.
Cautions and Drug Interactions
- Triptan combination — there is no documented interaction between ginger and any triptan. Using ginger first with a triptan as rescue therapy raises no known interaction.
- Nonsteroidal anti-inflammatory drugs combination — the additive antiplatelet and gastrointestinal-irritant effects are the concern at chronic high doses; for acute migraine use of ginger + nonsteroidal anti-inflammatory drug once or twice per attack, the risk is minimal.
- Anti-CGRP gepants (ubrogepant, rimegepant) — no documented interaction; combination would be theoretically additive on the CGRP pathway if ginger's CGRP-modulating activity is real, but this has not been studied clinically.
- Warfarin and anticoagulants — the bleeding-risk caution from the other Benefits pages applies. For people on warfarin, regular ginger use is the situation in which international normalized ratio (INR) monitoring becomes relevant; acute single-attack doses are unlikely to be clinically significant.
- Selective serotonin reuptake inhibitors (SSRIs) and serotonin syndrome — the U.S. Food and Drug Administration-warning combination of triptans + selective serotonin reuptake inhibitors (theoretical serotonin syndrome risk, though rarely confirmed in practice) does not extend to ginger; the ginger−selective serotonin reuptake inhibitor (SSRI) combination has no documented risk.
- Pregnancy migraine — ginger is one of the few migraine-applicable remedies with pregnancy safety data (from the pregnancy-nausea trials) (where triptans, nonsteroidal anti-inflammatory drugs after 20 weeks, and ergots are all relatively or absolutely contraindicated). The Vutyavanich pregnancy-nausea evidence (see Nausea Relief page) is cited for doses up to 1.5 g/day in pregnancy. For pregnant women with migraine who cannot use triptans, ginger plus acetaminophen plus low-dose caffeine (a coffee or strong tea) is an acute combination some clinicians describe; no pregnancy migraine trial is cited here.
- Hormonal migraine and oral contraceptives — no documented interaction.
- Diabetes — chronic ginger use may modestly reduce blood glucose, which matters most for people on insulin or sulfonylureas, whose glucose-lowering effect it can add to.
Key Research Papers
- Maghbooli M, Golipour F, Moghimi Esfandabadi A, Yousefi M (2014). Comparison between the efficacy of ginger and sumatriptan in the ablative treatment of the common migraine. Phytotherapy Research 28(3):412–415. The pivotal head-to-head trial. — PubMed PMID: 23657930
- Rondanelli M, Fossari F, Vecchio V et al. (2020). Clinical trials on pain lowering effect of ginger: a narrative review. Phytotherapy Research 34(11):2843–2856. — PubMed PMID: 32436242
- Mustafa T, Srivastava KC (1990). Ginger (Zingiber officinale) in migraine headache. Journal of Ethnopharmacology 29(3):267–273. The classic 1990 case-series proposal. — PubMed PMID: 2214812
- Cady RK, Goldstein J, Nett R et al. (2011). A double-blind placebo-controlled pilot study of sublingual feverfew and ginger (LipiGesic M) in the treatment of migraine. Headache 51(7):1078–1086. — PubMed PMID: 21631494
- Martins LB, Rodrigues AMDS, Rodrigues DF et al. (2019). Double-blind placebo-controlled randomized clinical trial of ginger (Zingiber officinale Rosc.) addition in migraine acute treatment. Cephalalgia 39(1):68–76. — PubMed PMID: 29768938
- Martins LB, Rodrigues AMDS, Monteze NM, Tibaes JRB, Amaral MHA, Gomez RS, Teixeira AL, Ferreira AVM (2020). Double-blind placebo-controlled randomized clinical trial of ginger (Zingiber officinale Rosc.) in the prophylactic treatment of migraine. Cephalalgia 40(1):88–95. — PubMed PMID: 31398997
- Atkins T, Manger S, Albarqouni L (2026). Ginger for the treatment and prevention of migraine headaches: a systematic review and meta-analysis of randomised controlled trials. BMJ Evidence-Based Medicine, online ahead of print. — PubMed PMID: 42601183
- Hajhashemy Z, Golpour-Hamedani S, Eshaghian N, Sadeghi O, Khorvash F, Askari G (2024). Practical supplements for prevention and management of migraine attacks: a narrative review. Frontiers in Nutrition 11:1433390. — PubMed PMID: 39539367
- Black CD, Herring MP, Hurley DJ, O'Connor PJ (2010). Ginger (Zingiber officinale) reduces muscle pain caused by eccentric exercise. Journal of Pain 11(9):894–903. — PubMed PMID: 20418184
- Ozgoli G, Goli M, Moattar F (2009). Comparison of effects of ginger, mefenamic acid, and ibuprofen on pain in women with primary dysmenorrhea. Journal of Alternative and Complementary Medicine 15(2):129–132. — PubMed PMID: 19216660
- Rahnama P, Montazeri A, Huseini HF, Kianbakht S, Naseri M (2012). Effect of Zingiber officinale R. rhizomes (ginger) on pain relief in primary dysmenorrhea. BMC Complementary and Alternative Medicine 12:92. — PubMed PMID: 22781186
- Edwards SE, da Costa Rocha I, Williamson EM, Heinrich M (2015). Phytopharmacy: An Evidence-Based Guide to Herbal Medicinal Products. Ginger chapter. Wiley. (Textbook) — PubMed: Phytopharmacy ginger
- Yarnell E (2017). Herbal medicine and migraine. Alternative and Complementary Therapies 23(5):192–201. — doi:10.1089/act.2017.29131.eya
- Slavin M, Bourguignon J, Jackson K, Orciga MA (2016). Impact of food components on in vitro calcitonin gene-related peptide secretion — A potential mechanism for dietary influence on migraine. Nutrients 8(7):406. — PubMed PMID: 27376323
PubMed Topic Searches
Connections
- All Herbs
- Ginger Overview
- Ginger Benefits Hub
- Ginger for Nausea Relief
- Ginger Anti-Inflammatory & OA
- Ginger Digestive & Gastroparesis
- Migraine
- Chronic Pain
- Arthritis
- Dysmenorrhea
- Turmeric (Companion Anti-Inflammatory)
- Black Seed
- Magnesium (Migraine Prophylaxis)
- Vitamin B2 / Riboflavin (Migraine Prophylaxis)
- Anti-Inflammatory Diet
- Feverfew — the partner herb in the LipiGesic-M sublingual migraine combination.
- History